Publication:
Biologic agents in psoriasis

Simple item page
dc.contributor.buuauthorBaşkan, Emel Bülbül
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentDermatoloji Ana Bilim Dalı
dc.contributor.orcid0000-0002-0144-3263
dc.contributor.researcheridAAH-1388-2021
dc.contributor.scopusid6602518817
dc.date.accessioned2024-02-27T07:30:37Z
dc.date.available2024-02-27T07:30:37Z
dc.date.issued2008-12
dc.description.abstractPsoriasis is a chronic, inflammatory disease affecting 1-3% of population. Advances in the pathogenesis of psoriasis and biotechnology have led to the development of targeted therapy named biologic agents. in this review, general information on biologic drugs are presented and literature on four biologic agents available in our country for moderate to severe plaque psoriasis has been summarized. Mechanisms of action, indications and dosage, results of clinical studies and safety profiles of each biologic agent are discussed.
dc.identifier.citationBaşkan, E. B. (2008). "Biologic agents in psoriasis". Turkderm Deri Hastaliklari ve Frengi Arsivi, 40(Supplement 2), 42-50
dc.identifier.endpage50
dc.identifier.issn1019-214X
dc.identifier.issn1308-6294
dc.identifier.issueSupplement 2
dc.identifier.scopus2-s2.0-63149181435
dc.identifier.startpage42
dc.identifier.urihttps://hdl.handle.net/11452/39986
dc.identifier.volume42
dc.identifier.wos000263169900006
dc.indexed.scopusScopus
dc.indexed.wos6602518817
dc.language.isoen
dc.publisherVakıf Gureba Eğitim ve Araştırma Hastanesi Kliniği
dc.relation.journalTurkderm Deri Hastaliklari ve Frengi Arsivi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectDermatology
dc.subjectAdalimumab
dc.subjectBiologics
dc.subjectEfalizumab
dc.subjectEtanercept
dc.subjectInfliximab
dc.subjectPsoriasis
dc.subjectChronic plaque psoriasis
dc.subjectRandomized controlled-trial
dc.subjectPatient-reported outcomes
dc.subjectLong-term
dc.subjecttreatment
dc.subjectPhase-III
dc.subjectDouble-blind
dc.subjectEfalizumab therapy
dc.subjectRheumatoid-arthritis
dc.subjectOpen-label
dc.subjectInfliximab monotherapy
dc.subject.emtreeAdalimumab
dc.subject.emtreeAlefacept
dc.subject.emtreeAntipsoriasis agent
dc.subject.emtreeEfalizumab
dc.subject.emtreeEtanercept
dc.subject.emtreeInfliximab
dc.subject.emtreeTumor necrosis factor alpha inhibitor
dc.subject.emtreeBiotechnology
dc.subject.emtreeClinical research
dc.subject.emtreeDisease severity
dc.subject.emtreeDrug indication
dc.subject.emtreeDrug mechanism
dc.subject.emtreeDrug safety
dc.subject.emtreeHuman
dc.subject.emtreePathogenesis
dc.subject.emtreePsoriasis
dc.subject.emtreeReview
dc.subject.scopusPustulosis Palmoplantaris; Ustekinumab; Etanercept
dc.subject.wosDermatology
dc.titleBiologic agents in psoriasis
dc.typeArticle
dc.wos.quartile
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Dermatoloji Ana Bilim Dalı
local.indexed.atWOS
local.indexed.atScopus

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

İndeksli Yayınlar / Indexed Publications